News & Conferences

VaxForm, LLC Awarded QTDP Grant

Nov 1, 2010 12:00 am

Lehigh Valley, PA.  VaxForm, LLC was awarded a qualified therapeutic discovery project grant to further develop their Streptococcus pyogenes vaccine candidate.  VaxForm,  in collaboration with the United States Army Medical Research Institute of Infectious Diseases, is in the pre-clinical development stage of their novel vaccine based on a recombinant protein fusion between streptococcal pyrogenic exotoxin B (SpeB), a cysteinyl protease, and streptococcal pyrogenic exotoxin A (SpeA), a superantigen.  This allows for broad protection against multiple strains.  Streptococcus pyogenes is a gram-positive bacterium which causes multiple diseases in humans.  Worldwide an estimated 500,000 people die annually from S.pyogenes infection. An additional 600 million cases of pharyngitis occur each year.  The annual cost to the health system in the US alone is estimated at $220 - 540 million per year to manage pharyngitis in children.  An effective vaccine would allow for millions of dollars in medical cost savings by reducing the rate of disease in the population.

About VaxForm

VaxForm, is a Limited Liability Company, based in Pennsylvania, performing consulting business in vaccine formulation development. VaxForm can provide the expertise required to efficiently move your product through discovery, pre-formulation characterization, formulation development and into clinical trials. VaxForm tailor each project to your needs and put together a solution to respect the environment and strategy of your business, and reach an effective solution to achieve your objectives to responds to the spectrum of global health needs.